Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 963-969

  Huang, Huang F ^a   Jann, Michael W ^b   Wei, Fu Chuan ^c   Chang, Teng Ping ^d   Chen, Jeng Shong ^a   Juang, Dong Juiing ^a   Lin, Shih Ku ^a   Lam, Y W Francis ^e   Chien, Ching Piao ^a   Chang, Wen Ho ^a  

^a TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^b MERCER UNIVERSITY   (United States)

^c Hung Chi Psychiatric Hospital   (Taiwan)

^d Military 818 Psychiatry Hospital   (Taiwan)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; HALOPERIDOL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DOPAMINERGIC ACTIVITY; DRUG HALF LIFE; DRUG TOLERANCE; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY;

EID: 10544241183     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04764.x     Document Type: Article

References (27)

1. Jann MW: Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 1988;8:100-116.
2. Sathananthan GL, Sanbghvi I, Phillips N: MJM 9022: correlation between neuroleptic potential and stereotypy. Curr Ther Res 1975;18:701-705.
3. D'Mello DA, McNeil JA, Harris W: Buspirone suppression of neuroleptic induced akathisia: multiple case reports. J Clin Psychopharmacol 1989;9:151-152.
4. Sovner R, Parnell-Sovner N: Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 1989;9:61-62.
5. Gammans RE, Mayol RF, LaBudde JA: Metabolism and disposition of buspirone. Am J Med 1986;80(suppl 3B):41-51.
6. Froemming JH, Lam YWF, Jann MW, Davis CM: Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989;17:396-423.
7. Inaba T, Kovacs J: Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 1989;17:330-333.
8. Tyndale RF, Kalow W, Inaba T: Oxidation of reduced haloperidol to haloperidol: involvement of human P 450 IID6. Br J Clin Pharmacol 1991;31:655-660.
9. Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, Saklads R, Burch NR: Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984;4:138-142.
10. Altamura CA, Mauri MC, Cavallaro R, Gormi A: Haloperidol metabolism and antipsychotic effect in schizophrenia. Lancet 1987;2.814-815.
11. Bowen WD, Moses EL, Tolentino PJ, Walker JM: Metabolites of haloperidol display preferential activity at the receptors to dopamine D-2 receptors. Eur J Pharmacol 1990;177:111-118.
12. Jann MW, Chang WH, Davis CM, Chen TY, Deng HC, Lung FW, et al: Haloperidol and reduced haloperidol plasma levels in Chinese vs Non-Chinese psychiatric patients. Psychiatry Res 1989;30:45-52.
13. Conley R, Nguyen JA, Tamminga CA: Haloperidol kinetics and clinical response (abstract). Schizophr Res 1991;96:287.
14. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET: An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991;11:193-197.
15. Chang WH, Lin SK, Jann MW, Lam YWF, Chen TY, Chen CT, et al: Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol Psychiatry 1989;26:239-249.
16. Gibaldi M, Perrier D: Pharmocokinetics. Second edition. New York: Marcel Dekker, 1982.
17. Chang WH, Lam YWF, Jann MW, Chen H: Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacol 1992;106:517-522.
18. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarni RJ: Elevation of plasma concentratins of haloperidol after the addition of flouxetine. Am J Psychiatry 1991;148:790-792.
19. Molitor JA, Gammans RE, Carroll CM, LaBudde JA: Effect of buspirone on mixed function oxidase. Fed Proc 1985;44:1257.
20. Jajoo HK, Mayol RF, LaBudde JA, Blair IA: Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17:634-640.
21. Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ: Lack of interaction between cimetidine and buspirone. Pharmacotherapy 1987;7:72-79.
22. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmat JS, Shader RI: Interaction of cimetidine with triazolobenzodiazepines alprazolam and triazolam. Psychopharmacol 1983;80:275-278.
23. Barbee JG, Mancusco DM, Freed CR, Todorov AA: Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992;149:506-510.
24. Douyon R, Angrist B, Peselow E, Cooper T, Rotrosen J: Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry 1989;146:231-233.
25. Wolkowitz OM, Brier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D: Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenia patients. Arch Gen Psychiatry 1988;45:664-671.
26. Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH: A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993;33:1104-1109.
27. Bullen WW, Bivens DL, Gammans RE, LaBudde JA: The binding of buspirone to human plasma proteins. Fed Proc 1985;44: 1123.